| Miao Zhang,Zhaozhe Liu,Zhendong Zheng,Tao Han,Yaling Han,Min Song,Xiaodong Xie. Clinical observation of capecitabine monotherapy in elderly patients with advanced breast cancer. Oncol Transl Med, 2015, 1: 78-81. |
| 卡培他滨单药治疗老年晚期乳腺癌的临床观察 |
| Clinical observation of capecitabine monotherapy in elderly patients with advanced breast cancer |
| Received:November 19, 2014 Revised:April 01, 2015 |
| DOI：10.1007/s10330-014-0027-y |
| 中文关键词: 卡培他滨；老年晚期乳腺癌；药物疗法 |
| 英文关键词: capecitabine; elderly; advanced breast cancer; drug therapy |
| 基金项目:国家十二五重大新药创制平台子课题（2012ZX09303016-002）;2012年辽宁省科技攻关计划课题（2012225019） |
| Author Name | Affiliation | E-mail | | Miao Zhang | Graduate school,Da Lian medical university,Da Lian,Liaoning | 125505866@qq.com | | Zhaozhe Liu | Oncology Department, General Hospital of Shenyang Military Region, Shenyang 110840, China | 125505866@qq.com | | Zhendong Zheng | Oncology Department, General Hospital of Shenyang Military Region, Shenyang 110840, China | 125505866@qq.com | | Tao Han | Oncology Department, General Hospital of Shenyang Military Region, Shenyang 110840, China | 125505866@qq.com | | Yaling Han | Oncology Department, General Hospital of Shenyang Military Region, Shenyang 110840, China | 125505866@qq.com | | Min Song | Oncology Department, General Hospital of Shenyang Military Region, Shenyang 110840, China | 13309882697@163.com | | Xiaodong Xie* | Oncology Department, General Hospital of Shenyang Military Region, Shenyang 110840, China | 510503094@qq.com |
|
| Hits: 8880 |
| Download times: 10117 |
| 中文摘要: |
| 摘要：目的：观察单药卡培他滨治疗老年晚期乳腺癌的临床疗效及不良反应。方法：对36例老年晚期乳腺癌患者进行单药卡培他滨方案化疗，给予 卡培他滨 2000 mg／m2 ，分2次口服，第1～14天，21天为1周期，每两周期评价疾病疗效并观察其主要不良反应。结果：36例老年乳腺癌患者的中位化疗周期数为4个，其中临床完全缓解(CR)为2例，临床部分缓解（PR）为9例， 疾病稳定（SD）为15例，疾病进展（PD）为10例，总有效率（OR）为30.6%（11/36），疾病控制率（DCR）为72.2%（26/36）。治疗有效患者的中位疾病进展时间（TTP）为6个月，中位总生存时间（OS）为9.5个月。主要的不良反应包括骨髓抑制、消化道反应及口腔黏膜炎等，大多数反应为Ⅰ～Ⅱ度，Ⅲ～Ⅳ度不良反应主要为2例(12.5%)粒细胞减少和1例(6.7%)手足综合征。结论：卡培他滨单药治疗老年晚期乳腺癌可有效地控制疾病进展且不良反应可以耐受。 |
| 英文摘要: |
| Objective: The aim of the study was to evaluate the safety and efficacy of capecitabine mono-chemotherapy in elderly patients with advanced breast cancer.
Methods: The data from 36 cases of capecitabine monotherapy in elderly patients with advanced breast cancer were retrospectively analyzed. Oral administration of capecitabine 2000 mg/m2 twice daily (D1–14) for 21 days constituted a cycle. The effect of the disease and main adverse reactions were evaluated every 2 cycles.
Results: The data from 36 elderly patients were studied. The median number of chemotherapy cycles was 4. The total effective rate was 30.6% (11/36) and the disease control rate was 72.2% (26/36). The number of patients with clinical complete remission was 2, clinical partial response was 9, stable disease was 15, and progressive disease was 10. Where treatment was effective, the median time to progression was 6 months and the median overall survival was 9.5 months. The main adverse events were gastrointestinal reactions, bone marrow suppression, and oral mucositis; most of the reactions were grade 1 to 2. Grade 3 to 4 adverse reactions included granulocytopenia in 2 patients (12.5%) and hand-foot syndrome in 1 patient (6.7%).
Conclusion: Capecitabine monotherapy was effective in controlling disease progression, and adverse reactions were tolerated by elderly patients with advanced breast cancer. |
|
View Full Text
Download reader HTML全文 |
| Close |
|
|
|